MVA Smallpox Vaccine

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

MVA Post-Event: Administration Timing and Boost Study

High Dose IMVAMUNE® in Vaccinia-Naive Individuals

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

ACAM 3000 MVA at Harvard Medical School

Combination Study With MVA BN and Dryvax

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive

Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine